KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBIT (2016 - 2025)

Historic EBIT for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$154.8 million.

  • CRISPR Therapeutics AG's EBIT fell 13961.73% to -$154.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$664.6 million, marking a year-over-year decrease of 4243.91%. This contributed to the annual value of -$664.6 million for FY2025, which is 4243.88% down from last year.
  • Per CRISPR Therapeutics AG's latest filing, its EBIT stood at -$154.8 million for Q4 2025, which was down 13961.73% from -$132.1 million recorded in Q3 2025.
  • CRISPR Therapeutics AG's 5-year EBIT high stood at $762.6 million for Q2 2021, and its period low was -$229.3 million during Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's median EBIT value was -$132.2 million (recorded in 2023), while the average stood at -$82.7 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 104513.25% in 2021, then plummeted by 19282.15% in 2024.
  • Over the past 5 years, CRISPR Therapeutics AG's EBIT (Quarter) stood at -$145.7 million in 2021, then grew by 9.72% to -$131.5 million in 2022, then soared by 152.9% to $69.6 million in 2023, then tumbled by 192.82% to -$64.6 million in 2024, then tumbled by 139.62% to -$154.8 million in 2025.
  • Its EBIT was -$154.8 million in Q4 2025, compared to -$132.1 million in Q3 2025 and -$229.3 million in Q2 2025.